Navigation Links
Rigel to Present at Citi's Biotech Day
Date:3/27/2009

SOUTH SAN FRANCISCO, Calif., March 27 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at Citi's 4th Annual Biotech Day in New York City on Wednesday, April 1st at 10:40 a.m. EDT.

To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

    Contact: Ryan Maynard
    Phone: 650.624.1284
    Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Rigel to Present at BIO Investor Forum 2007
2. Rigel to Present Research Programs at Scientific Conferences
3. Rigel Announces Pricing of Public Offering of Common Stock
4. Rigel to Present at BIO CEO & Investor Conference
5. Rigel Announces Fourth Quarter and Year End 2007 Financial Results
6. Rigel to Host Update Conference Call
7. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
8. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
9. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
10. Rigel to Participate at the RBC Capital Markets Healthcare Conference
11. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... ... - Speeds ,Race for Time, to Find ... - Saves Valuable Research Money, LAS VEGAS, ... New York, are pleased to announce they have inked a,worldwide partnering agreement to commercialize ...
... the international,investment house specialising in medical sciences, said ... UK biotech sector,despite the most severe market conditions., ... and a development,of Merlin Biosciences, was instrumental in ... specialist dermatology company, to make a,significant product acquisition ...
... Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical ... today announced that it will,host a Research Day ... EDT. A,webcast of the presentations will be available ... -- Strategic Company Overview, Jonathan Lim, M.D., President ...
Cached Biology Technology:Samaritan Partners 'Forgetful' Rat Model to Taconic to Commercialize 2Samaritan Partners 'Forgetful' Rat Model to Taconic to Commercialize 3Excalibur - 'Transforming' Biotech Deals can Still be Achieved 2Halozyme Therapeutics to Host Research Day for Investors and Analysts 2
(Date:5/22/2013)... that can detect molecular variants in chemical mixtures ... most important, though time-consuming, processes in analytical chemistry. ... , post-doctoral researcher David Patterson, Professor of Physics John ... Free-Electron Laser Science (CFEL) in Hamburg, Germany developed a ... molecular variants apart, and to determine how much variant ...
(Date:5/22/2013)... in a major new effort to educate the public ... people with clean water that looms ahead in the ... in the current edition of Chemical & Engineering ... Society (ACS), the world,s largest scientific society. , Bassam ... L. Schnoor, Ph.D., explain that shortages of reliable supplies ...
(Date:5/22/2013)... (May 22, 2013)The omega 3 fatty acids in fish ... diseaseso much so that the American Heart Association currently ... week, particularly fatty varieties rich in omega 3s. However, ... mystery. In a new study, scientists led by Jason ... this phenomenon by providing evidence that fish oil might ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3Fish oil may help the heart beat mental stress 2
... and sea levels in the centuries to come? Are we ... the oceans on the rise? Can aquaculture be environmentally sustainable? ... of coastal fisheries? , Most importantly, what can governments, industry ... news media are invited to join leading international researchers and ...
... used to create early-stage sperm cells for the first time, ... about how sperm cells are created. , The research ... Reproduction: Gamete Biology, was carried out in Germany* by a ... the University of Göttingen but now of the North-east England ...
... immuno-contraceptive vaccine causes an animal's immune system to produce ... in the reproductive process. The antibodies can act against ... or the production of sperm and ova. ... nearly 20 years ago, regard it as more humane ...
Cached Biology News:Are we killing the world's oceans? 2Early-stage sperm cells created from human bone marrow 2Manipulating nature: Scientists query wildlife birth-control method 2
... (AMV RT) catalyzes the polymerization of DNA ... (1). It requires a primer (DNA primers ... well as Mg2+ or Mn2+. The enzyme ... nonionic detergents and sulfhydryl compounds stabilize the ...
... - Neurosphere is a system designed for ... neurospheres in a serum free environment. The kit ... which has been optimized for neural stem cell ... Genes & Development 10 :3129). Two growth ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... coli strain containing an overproducing clone of ... Transcriptase catalyzes the polymerization of DNA using ... copies of large mRNAs, >10 kb, may ... much lower RNase H activity than AMV ...
Biology Products: